Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry. Yet ...

Rheumatoid arthritis drugs fight pain and prevent joint damage. See a full list of RA medications, including NSAIDs, DMARDs, immunosuppressants, and others.

Learn about various treatment options for rheumatoid arthritis and how they help to manage symptoms, relieve pain, and slow disease progression.